Roche India and Cipla Limited have co-jointly launched the COVID-19 antibody cocktail known as Casirivimab and Imdevimab in India. According to reliable sources, the first batch of this multi-pack antibody cocktail will be made available soon, with the second batch launching by mid-June.

For those unaware, Casirivimab and Imdevimab are human immunoglobulin G-1 (1gGI) monoclonal antibodies that are produced by joining the DNA of two different species in the laboratory. These antibodies were reported to be effective in treating high-risk patients before their condition deteriorates and are known to reduce the hospitalization risk as well as fatality by 70%.

Each pack that contains one vial of Casirivimab and Imdevimab of 1200mg can treat two patients and will be available at around USD 800. Meanwhile, the maximum retail price of each pack is kept at approximately USD 1640.

Cipla, with its strong logistical hold, will distribute the dose packs throughout the country. As per the reports, these antibody dose packs will be available via leading hospitals and COVID treatment centers.

India’s national regulatory body for pharmaceuticals, the Central Drugs Standards Control Organization (CDSCO), has reportedly authorized an Emergency Use Authorization for this antibody cocktail. Roche India’s and Cipla’s multi-pack antibody cocktail has also received a similar EUA in the U.S. as well as various EU countries.

V. Simpson Emmanuel, the Managing director and CEO of Roche India was quoted saying that the availability of the antibody cocktail is expected to drastically reduce hospitalization rates which will subsequently lower the pressure on healthcare bodies.

The antibody cocktail will treat mild to moderate COVID-19 in adults and minors above 12 years of age weighing at least 40kgs. However, the dose will be given to only confirmed COVID-19 patients who do not require oxygen support.

Source credits –

https://www.moneycontrol.com/news/business/sebi-provides-some-compliance-exemption-to-ledo-tea-company-for-delisting-6933831.html